EP Patent

EP3708564B1 — A solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Assigned to Vertex Pharmaceuticals Inc · Expires 2024-10-09 · 2y expired

What this patent protects

Patent listed against Kalydeco.

Drugs covered by this patent

Patent Metadata

Patent number
EP3708564B1
Jurisdiction
EP
Classification
—
Expires
2024-10-09
Drug substance claim
No
Drug product claim
No
Assignee
Vertex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.